Status:
COMPLETED
Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To assess the efficacy and safety of PF-3512676 administered in combination with erlotinib in patients with advanced EGFR-positive non-small cell lung cancer after failure of at least one prior chemot...
Eligibility Criteria
Inclusion
- Advanced, EGFR-positive NSCLC
- ECOG Performance Status 0, 1 or 2
- Measurable disease
Exclusion
- Known CNS metastasis
- Pre-existing autoimmune or antibody mediated disease
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00321815
Start Date
August 1 2006
End Date
June 1 2010
Last Update
December 23 2010
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Daphne, Alabama, United States, 36526
2
Pfizer Investigational Site
Huntsville, Alabama, United States, 35805
3
Pfizer Investigational Site
Mobile, Alabama, United States, 36608
4
Pfizer Investigational Site
Corona, California, United States, 92879